Blood test could replace biopsies for breast cancer subtyping

NCT ID NCT07574749

Recruiting now Diagnosis Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study is testing a new blood-based diagnostic that looks at tiny particles from breast cancer cells to determine the cancer's molecular subtype. Researchers will compare results from this test with standard tissue biopsies in 1,500 people with advanced breast cancer. If accurate, the test could offer a quicker, less invasive way to guide treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could provide a less invasive way to determine breast cancer subtypes, helping doctors choose more effective treatments.
What could go wrong: This is an early-phase exploratory study, so the test may not prove accurate enough for routine use. Results need confirmation in larger, more diverse trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.